AZTA vs BVS: fair value comparison
Azenta, Inc. and Bioventus Inc. · Updated 2026-09-12
AZTA currently screens as fairly valued while BVS screens as overvalued. Within Healthcare, AZTA currently sits closer to the top of our discount ranking. BVS carries the stronger quality grade.
| AZTA | BVS | |
|---|---|---|
| Verdict | Fairly valued | Overvalued |
| Last price | $31.57 | $13.67 |
| 12-month range | $21.18–$37.53 | $6.56–$13.67 |
| Sector rank | #84 of 113 Healthcare | #89 of 113 Healthcare |
| Quality grade | D | C |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | — | Undervalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: AZTA fair value analysis · BVS fair value analysis